Gene expression profiling in breast cancer – design of a pooled database to address open questions

Publication Name: European Surgery

Author(s): Michaël Knauer, Etienne Wenzl, Emiel J Rutgers, Sabine C Linn, Laura J van't Veer

BACKGROUND: The Netherlands Cancer Institute used DNA microarray analyses to identify a 70-gene expression profile strongly predictive of a short interval to distant metastases in breast cancer. For patients with small tumors, the signature is not yet adequately validated. Furthermore, … Continued

The 70-gene prognosis-profile predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study

Publication Name: Breast Cancer Research and Treatment

Author(s): Mook, S, Schmidt, M.S., Viale, G

Purpose: The 70-gene prognosis-signature has shown to be a valid prognostic tool in node-negative breast cancer. Although axillary lymph node status is considered to be one of the most important prognostic factors, still 25–30% of node-positive breast cancer patients will … Continued

Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer.

Publication Name: Annals of Oncology

Author(s): Goldhirsch A, Ingle JN, Gelber RD et al.

The 11th St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers. Any positive level of estrogen receptor … Continued

I-SPY 2 – An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Publication Name: Clinical Pharmacology Therapeutics

Author(s): Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ.

I-SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2) is a process targeting the rapid, focused clinical development of paired oncologic therapies and biomarkers. The framework is an adaptive phase II clinical … Continued

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.

Publication Name: European Journal of Cancer

Author(s): S. Mook, H. Bonnefoi, G. Pruneric, D. Larsimont, J. Jaskiewicz, M.D. Sabadell, G. MacGrogan, L.J. van’t Veer, F. Cardoso, E.J. Rutgers.

Purpose: The 70-gene prognosis-signature is a prognostic tool for early breast cancer analysis. In addition to scientific evidence, implementation of the signature in clinical trials and daily practice requires logistical feasibility. The aim of our study was to test logistics … Continued

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.

Publication Name: Breast Cancer Research and Treatment

Author(s): Marieke E. Straver, Annuska M. Glas, Juliane Hannemann, Jelle Wesseling, Marc J. van de Vijver, Emiel J. Th. Rutgers, Marie-Jeanne T. F. D. Vrancken Peeters, Harm van Tinteren, Laura J. van‘t Veer, Sjoerd Rodenhuis

The 70-gene signature (MammaPrintTM) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II–III patients … Continued

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Publication Name: The Breast

Author(s): Kathy S Albain, Soonmyung Paik, Laura van ’t Veer

Background: Multigene assays performed on the primary tumors from women with non- metastatic breast cancer provide useful prognostic information and discriminate excellent versus poor outcome potential in diverse clinical scenarios. Recently, analyses were conducted to determine if these assays predict … Continued

Clinical Application of the 70-Gene Profile: The MINDACT Trial

Publication Name: Journal of Clinical Oncology

Author(s): Cardoso F1, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ

The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid … Continued

Use of a 70-Gene Signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Publication Name: Lancet Oncology

Author(s): Jolien M Bueno-de-Mesquita MD, Prof Wim H van Harten MD, Valesca P Retel MSc, Laura J van 't Veer PhD, Prof Frits SAM van Dam PhD, Kim Karsenberg MSc, Kirsten FL Douma MSc, Harm van Tinteren PhD, Johannes L Peterse MD, Jelle Wesseling MD, Tin S Wu MSc, Douwe Atsma BSc, Prof Emiel JT Rutgers MD, Guido Brink BSc, Arno N Floore BSc, Annuska M Glas PhD, Rudi MH Roumen MD, Frank E Bellot MD, Cees van Krimpen MD, Prof Sjoerd Rodenhuis MD, Prof Marc J van de Vijver MD, Dr Sabine C Linn MD

Background: A microarray-based 70-gene prognosis signature [MammaPrint] might improve the selection of patients with node-negative breast cancer for adjuvant systemic treatment. The main aims of this MicroarRAy PrognoSTics in Breast CancER (RASTER) study were to assess prospectively the feasibility of … Continued

Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools

Publication Name: BMC Genomics

Author(s): Robert A Ach, Arno Floore, Bo Curry, Vladimir Lazar, Annuska M Glas, Rob Pover, Anya Tsalenko, Hugues Ripoche, Fatima Cardoso, Mahasti Saghatchian d'Assignies, Laurakay Bruhn and Laura J Van't Veer

Background: The increasing use of DNA microarrays in biomedical research, toxicogenomics, pharmaceutical development, and diagnostics has focused attention on the reproducibility and reliability of microarray measurements. While the reproducibility of microarray gene expression measurements has been the subject of several … Continued